Cochlear Limited (CHEOY)
| Previous close | 68.20 |
| Open | 70.58 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 69.82 - 70.58 |
| 52-week range | 63.18 - 94.21 |
| Volume | |
| Avg. volume | 9,096 |
| Market cap | 9.285B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 51.20 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.09 (1.63%) |
| Ex-dividend date | 25 Mar 2022 |
| 1y target est | N/A |
- PR Newswire
Cochlear announces 2022 winners of annual scholarships
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced today the winners of the 20th annual Graeme Clark and the 11th annual Anders Tjellström Scholarships. The scholarships, named after two pioneers of the hearing implant industry, recognize Cochlear™ Nucleus® Implant, Cochlear Baha® System and Cochlear Osia® System recipients in the United States and Canada who uphold the Cochlear ideals of leadership and humanity, and demonstrate high academic achievement.
- PR Newswire
FDA approves Cochlear Nucleus Implants for unilateral hearing loss/single-sided deafness
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval of Cochlear™ Nucleus® Implants for the treatment of unilateral hearing loss (UHL)/single-sided deafness (SSD).
- PR Newswire
Cochlear announces FDA approval and FDA clearance of first-of-its-kind Remote Care capabilities for Nucleus and Baha Systems
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval and clearance in the last month for its Cochlear™ Remote Assist solution in the Nucleus® and Baha® Systems. The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution are the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.
